Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial)
Mauro Maioli, MD*,
Francesco Bellandi, MD,
Mario Leoncini, MD,
Anna Toso, MD and
Roberto Piero Dabizzi, MD
Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy.
View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Flow of Patients Through the Trial
AMI = acute myocardial infarction; CABG = coronary artery bypass grafting; LBBB = left bundle branch block; PCI = percutaneous coronary intervention.
|
|
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 TIMI Flow and MBG at Basal Angiography
Basal angiography: Thrombolysis In Myocardial Infarction (TIMI) flow (left) and myocardial blush grade (MBG) (right) in the early versus late groups. Both parameters are significantly better in the early abciximab group with a higher percentage of TIMI flow grade 3 and MBG 3 (left: p = 0.001 vs. late group; right: p = 0.028 vs. late group).
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Left Ventricular Function According to Early and Late Abciximab
Left ventricular function according to early (blue bars) and late (red bars) abciximab. Ejection fraction (EF) (left) and wall motion score index (WMSI) (right) at baseline and at 1 month after primary angioplasty, and mean gain in EF and WMSI between the 2 time points. In the early abciximab patients, both functional parameters were significantly better compared with late abciximab patients (left: p = 0.014 vs. late group; right: p = 0.014 vs. late group); in the same patients, the mean gain in EF (left: p = 0.023 vs. late group) and in WMSI (right: p = 0.031 vs. late group) was significantly higher. Error bars indicate SDs of the mean.
|
|
|
